title: Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
abstract: BACKGROUND
  After premenopausal risk-reducing salpingo-oophorectomy (RRSO) to prevent ovarian cancer, the non-cancer-related morbidity and mortality may be increased if sex hormones are not replaced. Several guidelines recommend systemic hormone replacement therapy (HRT) to these women until the expected age of menopause. We aimed to study the use of HRT after RRSO.
  
  
  METHODS
  Participants were 324 women after RRSO and 11 160 postmenopausal controls. A subsample of 950 controls had undergone bilateral salpingo-oophorectomy (BSO). All participants completed the same questionnaire regarding HRT use. We compared HRT use in the RRSO group with the BSO controls using logistic regression.
  
  
  RESULTS
  Among the women aged ≤52 years without a history of breast cancer, 51.7% of the RRSO group and 48.7% of the BSO controls reported current use of systemic HRT (odds ratio 1.13, 95% confidence interval 0.72-1.76). Among the HRT users, systemic estrogen was used by 35.1% and 58.7% in the RRSO and BSO control groups, respectively (p = 0.001). Among the women aged >52 years, 16.8% of the RRSO group and 38.4% of the BSO controls (p < 0.001) used systemic HRT.
  
  
  CONCLUSIONS
  Among the RRSO women and BSO controls ≤52 years old without a history of breast cancer, relatively few were current users. If there are no contraindications, these women would benefit from systemic HRT. Additionally, almost 40% of the BSO controls >52 years used systemic HRT. Doctors should be aware of this practice and prescribe systemic HRT when indicated.
authors.affiliation: Department of Gynecology, Sørlandet Hospital Arendal, Arendal, Norway.|Research Unit, Sørlandet Hospital, Arendal, Norway.|Faculty of Medicine, University of Oslo, Oslo, Norway.
authors.forename: Nora
authors.identifier: http://orcid.org/0000-0002-7670-400X
authors.initials: N
authors.lastname: Johansen
authors.affiliation: Department of Gynecology, Sørlandet Hospital Arendal, Arendal, Norway.|Research Unit, Sørlandet Hospital, Arendal, Norway.
authors.forename: Astrid H
authors.initials: AH
authors.lastname: Liavaag
authors.affiliation: Department of Clinical Science, University of Bergen, Bergen, Norway.|Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway.
authors.forename: Ole-Erik
authors.initials: OE
authors.lastname: Iversen
authors.affiliation: Department of Gynecological Oncology, Oslo University Hospital Radiumhospitalet, University of Oslo, Oslo, Norway.
authors.forename: Anne
authors.initials: A
authors.lastname: Dørum
authors.affiliation: Institute of Community Medicine, University of Tromsø, Tromsø, Norway.
authors.forename: Tonje
authors.initials: T
authors.lastname: Braaten
authors.affiliation: Research Unit, Sørlandet Hospital, Arendal, Norway.|Division of Gynecology and Obstetrics, Department of Obstetrics, Oslo University Hospital Rikshospitalet, Oslo, Norway.|Norwegian National Advisory Unit on Women's Health, Oslo University Hospital, Oslo, Norway.
authors.forename: Trond M
authors.initials: TM
authors.lastname: Michelsen
mesh_terms: D015914:Estrogen Replacement Therapy; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D009664:Norway; D010051:Ovarian Neoplasms / Q000517:prevention & control / Q000601:surgery*; D010052:Ovariectomy; D058994:Salpingectomy; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
keywords: BRCA1 gene; BRCA2 gene; adverse effects; hereditary breast and ovarian cancer syndrome; hormone replacement therapy; menopause; ovariectomy